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Abstract
Background: Anti-angiogenic treatments of malignant tumors targeting vascular endothelial growth factor receptors
(VEGFR) tyrosine kinase are being used in different early stages of clinical trials. Very recently, VEGFR tyrosine kinase inhibitor
(Vetanalib, PTK787) was used in glioma patient in conjunction with chemotherapy and radiotherapy. However, changes in
the tumor size, tumor vascular permeability, vascular density, expression of VEGFR2 and other angiogenic factors in
response to PTK787 are not well documented. This study was to determine the changes in tumor size, vascular permeability,
fractional plasma volume and expression of VEGFR2 in PTK787 treated U-251 glioma rat model by in vivo magnetic
resonance imaging (MRI) and single photon emission computed tomography (SPECT). The findings were validated with
histochemical and western blot studies.
Methodologies and Principal Findings: Seven days after implantation of U251 glioma cells, animals were treated with
either PTK787 or vehicle-only for two weeks, and then tumor size, tumor vascular permeability transfer constant (K
trans),
fractional plasma volume (fPV) and expression of VEGFR2 and other relevant angiogenic factors were assessed by in vivo
MRI and SPECT (Tc-99-HYNIC-VEGF), and by immunohistochemistry and western blot analysis. Dynamic contrast-enhanced
MRI (DCE-MRI) using a high molecular weight contrast agent albumin-(GdDTPA) showed significantly increased K
trans at the
rim of the treated tumors compared to that of the central part of the treated as well as the untreated (vehicle treated)
tumors. Size of the tumors was also increased in the treated group. Expression of VEGFR2 detected by Tc-99m-HYNIC-VEGF
SPECT also showed significantly increased activity in the treated tumors. In PTK787-treated tumors, histological staining
revealed increase in microvessel density in the close proximity to the tumor border. Western blot analysis indicated
increased expression of VEGF, SDF-1, HIF-1a, VEGFR2, VEGFR3 and EGFR at the peripheral part of the treated tumors
compared to that of central part of the treated tumors. Similar expression patters were not observed in vehicle treated
tumors.
Conclusion: These findings indicate that PTK787 treatment induced over expression of VEGF as well as the Flk-1/VEGFR2
receptor tyrosine kinase, especially at the rim of the tumor, as proven by DCE-MRI, SPECT imaging, immunohistochemistry
and western blot.
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Introduction
Malignant gliomas are among the most devastating tumors, with
survival of only one to three years after diagnosis, even with the
best of treatments combining surgery, radiation and chemotherapy
[1,2]. Because of the hypervascular nature of glioblastoma and the
associated active angiogenesis, investigators have added anti-
angiogenic treatment as an adjuvant to normalize blood vessels
and control abnormal angiogenesis [3,4,5,6]. Angiogenesis is
essential for glioma tumor growth and metastasis. Malignant
glioma cells release vascular endothelial growth factor (VEGF), an
important regulator and promoter of angiogenesis [4]. Animal
studies have indicated that angiogenesis and increased vascular
permeability are essential for the proliferation and survival of
glioma cells [7]. Vascular endothelial growth factor, also termed
vascular permeability factor (VPF), is well-studied multifunctional
cytokine considered to play a pivotal role in the induction of tumor
angiogenesis. In vitro and in vivo data suggest that VEGF/VPF is an
endothelial-cell specific mitogen [8]. In addition to having a
mitogenic activity, VEGF/VPF is a potent vascular permeability
enhancer [8]. VEGF/VPF has been shown to increase the
permeability of micro vessels to plasma macromolecules with a
potency approximating 50,000 times that of histamine [9].
Expression of VEGF and its receptors correlates to the degree of
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factor for assessing patient survival [10]. High-affinity cognate
VEGF endothelial receptors are VEGFR-1/Flt-1 and VEGFR-2/
Flk-1/KDR and both receptors have been shown to be important
regulatory factors for vasculogenesis and physiological angiogen-
esis [11]. However, the interaction of VEGF/VPF with Flk-1/
VEGFR2 is thought to be more important for tumor angiogenesis
because it is essential for induction of the full spectrum of VEGF/
VPF functions [12]. In fact, many compounds and molecules
developed to block VEGF/VPF activities mediated by Flk-1/
VEGFR2 have been shown to have antiangiogenic activity in
animal models [13,14]. One such molecule is PTK787 that
inhibits the phosphorylation of Flk-1/VEGFR2 and Flt-1
receptors by binding to and inhibiting the protein kinase domain
of these receptors [15]. By directly inhibiting the phosphorylation
of the VEGF/VPF receptor tyrosine kinases, PTK787 suppresses
angiogenesis induced by VEGF/VPF. At slightly higher doses, it
also inhibits PDGF receptor tyrosine kinase [15]. PTK787
demonstrated efficacy in preclinical and Phase I/II trials where
it significantly reduced tumor vessel density and in some cases
induced tumor regression [12]. PTK787 significantly inhibited
growth of breast tumors in vivo and disrupted tumor microvascu-
lature after five days of treatment [10]. However, it has also been
noted that continued anti-angiogenic therapy targeting only the
VEGF-VEGFR system might activate pro-angiogenic factors
other than VEGF, such as basic fibroblast growth factor (bFGF),
stromal derived factor 1 (SDF-1) and Tie2 [5], and may mobilize
circulating endothelial cells and bone marrow derived precursor
cells that are known to promote angiogenesis [5,16,17]. Thus,
the inhibitory therapy targeting VEGF and/or VEGFRs may
paradoxically end up enhancing angiogenic and pro-growth
responses. Moreover, abundant VEGF over expression has been
demonstrated in human malignant glioma animal model [4].
However, there has been no report on the changes in the
expression pattern of different angiogenic factors in glioma
following treatment with antiangiogenic agents.
Many pre-clinical and clinical studies have shown that Dynamic
Contrast Enhancement (DCE) magnetic resonance imaging (MRI)
can assess tumor perfusion to predict tumor angiogenesis and
tumor response to anti-angiogenic therapy [18,19]. This method
monitors the pharmacokinetic uptake and wash-out of a MRI
contrast agent within the extracellular space of tumor tissues that
can be used to evaluate a vascular permeability coefficient (K
trans),
which has been shown to correlate with tumor perfusion and
angiogenesis. Vascular permeability can be measured with a
macromolecular contrast agents and small molecular agents;
however these two agents are not equally sensitive to the cancerous
tissues [20]. Macromolecular contrast agents are more sensitive
to the differences in vascular permeability exhibited by drug
treatment. Macromolecular contrast agent, albumin-(GdDTPA)
have a spherical diameter of ,6 nm and it appears to have the
best balance between payload and size needed for DCE MRI
studies [18,19]. Therefore, albumin-(GdDTPA) has been used by
many groups for MRI assessment of vascular permeability in
experimental human glioma model. GdDTPA was used to detect
and measure hypothesized changes in the tumor microvasculature
induced by the blockade of VEGF receptors, as well as the
accompanying changes in fractional plasma volume (fPV) and
vascular permeability to the macromolecules. In an animal breast
tumor model a high correlation between antiangiogenic therapy
(bevacizumab) and response in the tumor vascular bed was
demonstrated by using macromolecular contrast agent [21].
Availability of noninvasive assessment of vascular physiology
within the tumor and its surrounding tissue would provide an
extremely useful marker of response, and more critically, of non-
response to antiangiogenic therapy.
Imaging modality such as single photon emission computed
tomography (SPECT) can be used to analyze VEGF induced
signaling pathways in response to antiangiogenic (PTK787)
therapy. The effectiveness of treatment in rat glioma tumor
vasculature can be easily assessed by monitoring a biomarker
response (vascular surrogate) to PTK87 therapy. Since VEGFR2 is
over expressed in tumor vasculature (40,000 copies/endothelial
cell) and has a high binding affinity (Ka=5 to 77610
14 M
21)t o
VEGF [22], VEGF receptors have been targeted as anti- and pro-
angiogenic therapeutic agents as well as angiogenesis mediator
based imaging agents [23,24]. In an experimental breast cancer
mouse model, VEGFR2 expression has been detected by
Technetium-99m pertechnetate (Tc-99m) labeled VEGF [24].
Recently, site specific labeled Tc-99m-hydrazine nicotinamide
(HYNIC)-VEGF has been used for the imaging of mouse model
tumor (4T1 murine mammary carcinoma) vasculature before and
after antiangiogenic therapies [22]. Backer et al. reported
recombinant single-chain VEGF with a cysteine-containing tag
that allows the site specific labeling of Tc-99m-HYNIC and other
imaging agents [24]. All the studies showed that the accumulation
of Tc-99m-HYNIC labeled VEGF derivatives was VEGFR2
receptor mediated. However, there has been no report on in vivo
showing of the expression of VEGFR2 in glioma following
treatment with antiangiogenic agent.
The purposes of this study were to determine: 1) whether
antiangiogenic therapy using PTK787 effectively decreased the
size of implanted glioma (U251) in a rat model, 2) the changes in
expression of angiogenic factors in and around the tumors in
response to PTK 787, 3) whether changes in vascular parameters
could be determined in vivo by MRI and 4) whether changes in the
expression of VEGF receptors could be determined by in vivo
SPECT scanning. The findings were validated with immunohis-
tochemistry and western blot studies.
Results
Tumor Size
Vehicle and PTK787 treated rats were randomly selected from
U-251 implanted tumors. Randomly selected animals from both
groups also underwent pre treatment MRI to determine the
growth of tumors. Pre-treatment tumor volumes were similar in
both groups. However, significant differences (p=,0.001) were
observed in the volume of the tumors in PTK787 treated group
compared to that of vehicle treated group (Figure 1A). The
changes were clearly visible on both, T2WI and post contrast
T1WI (Figure 2A). High signal intensity areas seen on T2WI
were larger in PTK787 treated tumors compared to that of vehicle
treated tumors.
DCE MRI
Signal intensity changes at the periphery and central parts of the
PTK787 and vehicle treated tumors are shown in Figure 1B and
1C, respectively. In the PTK787 treated tumors (Figure 1B),
compared to that of vehicle treated tumors, higher signal intensity was
observed at the peripheral part of the tumors as early as 3 minutes
post contrast administration and the differences in signal intensity
remained to the end of the dynamic MRI acquisition. On the other
hand, the signal intensity at the central part of the PTK787 treated
tumors did not change from the base line and this signal intensity was
significantly different (p=,0.05) from that of peripheral part of the
tumors as early as 3 minutes post contrast administration. The similar
signal intensity differences between peripheral and central parts of the
PTK787 Therapy in Rat Glioma
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where the signal intensity changes from the baseline were symmetrical
for both, peripheral and central parts of tumors.
Kinetic Analysis of DCE MRI
Figure 1D shows the K
trans values in PTK787 and vehicle
treated tumors, and in contra lateral brains. Significantly higher
(p=,0.05) K
trans values were observed at the peripheral part,
compared to that of the central part and the contra lateral brain of
the PTK787 treated tumors. However, similar significant differ-
ences between the peripheral and centralparts were not observed in
the vehicle treated animals. When we compared the K
trans values at
the peripheral part of the two groups of tumors, higher K
trans values
were observed in the PTK787 treated tumors, although significant
difference was not detected (p=0.14). In addition, higher fPV was
observed at the peripheral part of the PTK787 treated tumors
compared to that of the vehicle treated tumors (Figure 2B). Post
contrast T1WI also supported the K
trans maps’ findings where
PTK787 treated tumors showed rim enhancement at the peripheral
part of the tumors with central hollow (Figure 2A, B). Figure 2B
also shows the representative maps of K
trans and fPV.
In Vivo Expression of VEGFRs
To determine whether there were any changes in the expression
of VEGFRs in the PTK787 and vehicle treated tumors, animals
underwent SPECT scanning with Tc-99m tagged VEGF-c. All the
animals that were treated with PTK787 showed higher activity of
Tc-99-VEGF-c in the tumors (Figure 3) compared to that of the
animals that were treated with vehicle. The higher expression of
VEGFRs was also confirmed by western blotting and immuno-
histochemical studies (see below).
Immunohistochemistry and Vascular Morphology
There were no signs of necrosis within the tumor in both,
PTK787 and vehicle treated tumors. Figure 4 shows the
expression of HIF-1a, SDF-1, VEGF and vascular morphology
and density as detected by FITC-labeled tomato lectin. Numerous
HIF-1a positive cells were observed in the central part of the
vehicle treated tumors, whereas none to very few positive cells
were observed in the central part of the PTK-787 treated tumors.
Despite the differences in HIF-1a expression, both PTK787 and
vehicle treated tumors showed the expression of SDF-1, especially
at the peripheral parts. Both groups of tumors exhibited strong
expression of VEGF in the central tumor mass as well as at the
satellite tumor foci. FITC-labeled tomato lectin staining showed
multiple dilated vessels at the peripheral part of the PTK787
treated tumors. Both, the numbers and the morphology of the
vessels seen in PTK787 treated tumors were different from the
vessels that were observed in vehicle treated tumors. PTK787
treated tumors showed high level of expression of VRGFR2 and
Figure 1. Tumor volume, signal intensity changes and K
trans in PTK787 and vehicle treated tumors. Measurement of tumor volume from
the post contrast T1WI show significantly higher tumor volume in rats that received PTK787 (A). Signal intensity (SI) changes at the peripheral and
central parts of the tumors in PTK787 (B) and vehicle (C) treated animals show remarkable differences in the SI-change patterns. SI changes at the
peripheral part (m) in PTK787 treated tumor are significantly higher from that of central part (&) of the PTK787 treated tumors as early as 3 minutes
after the injection of contrast agent, which is obviously different from that of vehicle treated tumors. Analysis of K
trans values (D) shows significantly
higher K
trans at the peripheral part of PTK87 treated tumors, compared to that of the corresponding central part. Vehicle treated tumors did not show
any differences in K
trans values between the peripheral and central parts. Data are expressed as mean 6 SEM, n$3, * p,0.05.
doi:10.1371/journal.pone.0008727.g001
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tumor cells (Figure 5). Multiple cells in the brain (possibly
microglia) near the tumors also exhibited high expression of
VEGFR2 and VEGFR3. Although both receptors were also
expressed in the vehicle treated tumors, the number of cells
expressing the receptors in the surrounding brain was less
compared to that of PTK787 treated tumors. Both vehicle and
PTK787 treated tumors showed EGFR positive cells in the
tumors.
Western Blotting
Higher expression levels of VEGF, SDF-1 and HIF-1a were
observed at the peripheral part of the PTK787 treated tumors
compared to that of central part (Figure 6A). Similar expression
of the above mentioned angiogenic factors was also observed in
the vehicle treated tumors. However, semi quantitative densi-
tometry analysis of western blots, normalized to corresponding b-
actin expression, and the expression of the same factors in
contralateral brains showed different patterns of expression of
VEGF, SDF-1 and HIF-1a in PTK787 and the vehicle treated
tumors. All of the factors showed higher normalized values at the
peripheral part of PTK787 treated tumors compared to that of
central part and the similar patterns were not observed in the
vehicle treated tumors. Similarly, expression of VEGFR2,
V E G F R 3a n dE G F Rs h o w e dh i g h e rn o r m a l i z e dv a l u e sa tt h e
peripheral part of the PTK787 treated tumors compared to the
Figure 2. MRI and parametric analysis of PTK787 treated and vehicle treated tumors. (A) Representative cases from vehicle and PTK787
treated tumors show enhancement following administration of contrast agents (Post T1WI) and changes in T2WI. PTK787 treated tumor show larger
tumor with prominent rim enhancement and central hollow compared to that of vehicle treated tumor. T2WI also show larger area of high signal
intensity beyond the margin of enhancement (arrows). (B) Representative cases from vehicle and PTK787 treated tumors showing K
trans, fractional
plasma volume (fPV) and corresponding post contrast T1W images. Clearly increased K
trans and fPV at the periphery of PTK787 treated tumor
(calculated K
trans and fPV maps are adjusted to same scale level for both vehicle treated and PTK787 treated tumors) indicate higher permeability and
fPV, which are in agreement with the findings of dilated vessels at the peripheral part of PTK787 treated tumors (see below).
doi:10.1371/journal.pone.0008727.g002
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different in the vehicle treated tum o r s .I ti st on o t et h a tP T K 7 8 7
t r e a t e dt u m o r ss h o w e dl o w e rn o r m a l i z e dv a l u e so fV E G F R 2a n d
EGFR both at the periphery and central parts of the tumors
compared to that of corresponding contralateral brain; whereas
vehicle treated tumors did not show any changes in the
normalized values of VEGFR2 and EGFR compared to that of
corresponding contralateral brain.
Discussion
Results from these studies showed that orally administered
PTK787 drug increased the tumor vascular permeability and
tumor growth in rat model of human glioma. Surprisingly, even
post contrast T1WI showed distinct differences between PTK787-
and vehicle-treated tumors. The MR images showed bright
contrast enhancement at the tumor rim and less contrast in the
Figure 3. SPECT analysis of in vivo accumulation of Tc-99m-HYNIC-VEGF-c. VEGF-c (which targets both VEGFR2 and VEGFR3) was tagged
with HYNIC chelators and then labeled with Tc-99m-pertechnetate (Tc-99m) and injected intravenously in PTK787 and vehicle treated rats. One hour
after injection, SPECT images were obtained using dedicated animal scanner. All PTK787 treated rats showed increased accumulation of Tc-99m-
HYNIC-VEGF-c in the tumors (lower panel, arrows) compared to that of vehicle treated tumors (upper panel, arrows).
doi:10.1371/journal.pone.0008727.g003
Figure 4. Immunohistochemistry of PTK787 and vehicle treated tumor showing expression of VEGF, HIF-1a, SDF-1 and vessel
morphology. Expression of vascular endothelial growth factor (VEGF) (dark brown colored) at different parts of the PTK787 treated and vehicle
treated tumors. There were no differences observed in the expression of VEGF on immunohistochemistry at different parts of the tumors treated with
either PTK787 or vehicle. However, delineation of vessels using FITC tagged tomato lectin indicated higher number of dilated vessels at the tumor
periphery in rats that received PTK787 treatment. These dilated vessels may be indicative of increased permeability, fPV and signal intensity changes
in PTK787 treated tumors (see Figures 1 and 2). Increased permeability may also be due to increased VEGF expression. HIF-1a expression was
mostly seen in the central part of the vehicle treated tumors (arrows), however, SDF-1 expressions were observed both in PTK787 and vehicle treated
tumors (arrows).
doi:10.1371/journal.pone.0008727.g004
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intensity areas beyond the margin of post-contrast enhancement on
T1WI. Analysis of the signal intensity ratio (tumor rims versus
contra lateral brains) showed significantly higher values as early as
3 minutes after the administration of contrast agents. Our results
demonstrated the unexpected, paradoxical effects of antiangiogenic
treatment with VEGFRs inhibitors. Malignant gliomas are
hypervascular tumors characterized by release of vascular endothe-
lial growth factor (VEGF), an important regulator and promoter of
angiogenesis [4]. Animal studies indicated that angiogenesis and
increased vascular permeability are essential for the proliferation
and survival of glioma cells [7]. Therefore, it was thought that anti-
angiogenic therapy targeting VEGF or VEGF receptors (VEGFRs)
would become an effective tool for controlling malignant glioma.
However, our results are contradictory to this hypothesis and
contradict the recent studies that reported decrease in tumor size of
implanted glioma (and other tumors) as well as the decrease in
permeability after treatment with VEGFRs inhibitor [25,26].
However, in these reported studies, the investigators started the
treatment soon after implantation and therefore might have not
allowed for the sufficient time for the clinically relevant tumor
angiogenesis to be generated. In our study, we started PTK787
treatment 7 days after tumor implantation, to mimic the clinical
scenario of a developed malignant glioma with extensive angiogen-
esis. Recently, tyrosine kinase inhibitors (such as vetanalib) that
target different VEGFRs have also been used in clinical trials [5,6]
with a limited success. However, it has been noted that continued
anti-angiogenic therapy targeting only the VEGF-VEGFR system
might activate pro-angiogenic factors other than VEGF, such as
basic fibroblast growth factor (bFGF), stromal derived factor 1
(SDF-1) and Tie2 [5], and may mobilize circulatingendothelial cells
and bone marrow derived precursor cells that are known to
promote angiogenesis [5,16,17]. Our results also showed increased
expression of VEGF, HIF-1a, SDF-1 following the treatment with
PTK787, indicating activation of pro-angiogenic factors, which
may cause more angiogenesis and increase in vascular permeability.
This effect is in part due to the accumulation of endothelial
progenitor cells, since HIF-1a induced increase in SDF-1expression
is a strong chemo-attractant for endothelial progenitor cells [27].
Importance of DCE MRI in Measuring Vascular
Permeability in Response to Therapy
DCE MRI has been used to validate the effect of anti-
angiogenic [28], anti-vascular [29], radiation [30] and focused
ultrasound therapies [31], to evaluate dose response [32] and to
predict therapeutic responses in pre-clinical and clinical tests [33].
The results from many DCE MRI studies have been correlated to
microvessel densities [34], tumor grades [35] and expression of
VEGF [20]. There are only few reports on assessing response to
PTK787 treatment of breast cancer or glioma models using DCE-
MRI methods. Preliminary reports have shown that K
trans
provides an early measure of response to therapy, with responding
tumors showing a reduction in K
trans values. Non-responding
tumors predominantly showed an increasing range of K
trans
values; in well-perfused tissues this reflected changes in microvas-
cular permeability. These techniques have also been employed in
phase I/II clinical trials [32] of a VEGF inhibitor tyrosine kinase
(PTK787), in which a reduction in K
trans value has been reported;
however, investigators also noticed refractory cases following long-
term use of antiangiogenic treatment [5]. From PTK787
antiangiogenic therapy point of view, we expected to observe a
decrease in vascular permeability due to the interruption of
receptors tyrosine kinase dependent pathway. However, our
finding of an increase in K
trans under PTK787 treatment is
contradictory and conflicts with the results reported by other
groups [10,12,15]. In this study, DCE-MRI data showed a
Figure 5. Immunohistochemistry of PTK787 and vehicle treated tumor showing expression of VEGFR2, VEGFR3 and EGFR.
Immunohistochemistry confirmed the findings of SPECT studies, where PTK787 treated tumors showed increased expression of VEGFR2 and VEFGR3
at the peripheral parts of the tumors, especially around the vessels (arrows) compared to that of vehicle treated tumors (right column). Both PTK787
(lower panel, left column) and vehicle treated (lower panel, right column) showed expression of EGFR in the tumors. Lower panel, middle column
show no brown cells in negative control slide.
doi:10.1371/journal.pone.0008727.g005
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trans values in U251 tumors treated with
PTK787, but no change in the vehicle treated group. The
increased values of K
trans correctly reflected the findings of
histochemistry and western blot analysis, where vascular mor-
phology and densities as well as the expression of VEGF and
VEGF receptors were shown to be upregulated in PTK787 treated
tumors. Our findings are in agreement with recently published
data reporting an increase of permeability transfer constant under
bevacizumab treatment [36]. Bevacizmab is a human-based
antibody against VEGF. Our results demonstrate that blockade
of VEGFRs signaling pathway may stimulate an alternative
pathway for tumor growth and angiogenesis and the changes can
be determined by DCE MRI.
Activation of Alternate Pathways for Angiogenesis and
the Importance of Our Findings for Future Treatment
Because of the hypervascular nature of glioblastoma and
associated active angiogenesis, investigators have added anti-
angiogenic treatment as an adjuvant to normalize the blood vessels
and control the abnormal angiogenesis [3,4,5,6]. Different targets
have been selected to control abnormal angiogenesis. Bevacizu-
mab, a humanised monoclonal antibody against VEGF is in
clinical trial. Bevacizumab is commonly combined with cytotoxic
chemotherapy and resulted in dramatic improvement on radio-
graphic images, prolongation of progression free survival and less
need for corticosteroids [4]. However, prolonged use of bevaci-
zumab or cessation of anti-angiogenic treatment in glioma patients
resulted in deteriorated clinical outcome [4,6]. Different pro-
angiogenic receptor tyrosine kinase inhibitors such as vetanalib,
cediranib, sunitinib, etc have been used in clinical trails with
varying degree of success [5,37]. These receptor blockers were
originally used for colorectal carcinoma and then later in glioma
patients as adjuvants to the established treatments. Initial clinical
trails showed remarkable improvement on MRI images with
respect to tumor size and vascular permeability [5]. However,
some reports showed extension of abnormal high signal intensity
areas on T2-weighted images away from the tumor mass, which
are thought to be due to invasive tumor mass (cells) [5]. Prolonged
treatment with these receptor blockers also negatively impacted
Figure 6. Western blot images and densitometry analysis of western blots. (A) Expression of different angiogenic factors (left panel) in the
vehicle- and PTK787 treated tumors from representative cases at the peripheral (P), central part of the tumors (C) and contralateral brains (B). Note
the increased expression of VEGF, SDF-1 and HIF-1a at the peripheral part of PTK787 treated tumors. Right panel shows the densitometry analysis of
the blot (normalized to b-actin and contralateral brain). The analysis also confirmed the finding of the blot. Note the patterns of VEGF, SDF-1 and HIF-
1a in PTK787 treated tumors which are different from that of vehicle treated tumors. (B) Densitometry analysis of VEGFR2, VEGFR3 and EGFR blot
(normalized to b-actin and contralateral brain). Expression of VEGFR2, VEGFR3 and EGFR showed higher normalized values at the peripheral part of
the PTK787 treated tumors compared to that of central part and the expression patterns are different in vehicle treated tumors. Please note that
PTK787 treated tumors showed lower normalized values of VEGFR2 and EGFR both at the periphery and central parts of the tumors compared to that
of corresponding contralateral brain; whereas vehicle treated tumors did not show any changes in the normalized values of VEGFR2 and EGFR
compared to that of corresponding contralateral brain. Data are expressed as mean 6 SEM, n=3.
doi:10.1371/journal.pone.0008727.g006
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failure of these anti-angiogenic treatments are the activation of
alternative angiogenesis pathways involved in expression of bFGF,
SDF-1 and VEGF and increased invasiveness of the tumor cells
[5,16,17]. Thus, the inhibitory therapy targeting VEGF and/or
VEGFRs may end up in paradoxically enhancing angiogenic and
pro-growth responses. In addition, as reported by our group and
other investigators, SDF-1 is one of the potent chemo attractants
for bone marrow derived endothelial progenitor cells due to the
presence of CXCR4 receptors in these cells [27,38], and it may be
involved in enhanced angiogenesis and invasiveness of the tumor
following treatment with VEGFRs inhibitors. Moreover, we have
also reported the role of inflammatory cytokine RANTES, which
also act as chemo attractant for these cells [39]. Any therapy would
cause enhanced inflammation in the tumor sites that in turn may
invite more endothelial progenitor cells and possibly increase
angiogenesis. Our current results showing increased vascularity
and permeability may support the hypothesis that increased
accumulation of endothelial progenitor cells play a role in tumor
angiogenesis. The increased expression of VEGF, SDF-1 and HIF-
1a at the peripheral part of the PTK-787 treated tumors must
have influenced permeability, dilatation of vessels (or increased
angiogenesis) and increased the invasiveness of the tumors.
Therefore, it is important to gain insight into the possible
mechanisms that are activated during anti-angiogenic treatment
to understand and potentially prevent its failure by using agents
that would not only block the angiogenic factor receptors but also
prevent the activation of alternative angiogenic pathways and
release of other angiogenic factors.
Importance of SPECT Studies in Delineating the
Activation of Alternate Pathways and Monitoring the
Treatment Progress
Investigators are now capable of easily tagging both, single
photon emission computed tomography (SPECT) and positron
emission tomography (PET) radioisotopes with peptides, amino
acids or proteins [40]. Although image resolution of SPECT is not
comparable to MRI and there is a need for anatomical images to
localize the exact site of radioactivity, the sensitivity of SPECT is
much superior to high resolution cellular MRI. The nuclear
medicine imaging technique would be much more suitable for
detecting expression of receptors in the tumor or receptor/ligand
interaction using the tagging of radioactive isotopes to the ligands.
There have been reports of making Tc-99m based SPECT agents
for determining the expression of different angiogenic factors in
the tumors [22,23,24,40]. However, most of the studies have been
performed in subcutaneous tumor models [24] and there has been
no study on determining the expression of angiogenic factors/
receptors in glioma following anti-angiogenic treatment utilizing
SPECT analysis. We have successfully tagged Tc-99m with
different proteins and peptides using the new generation chelator,
HYNIC (Hydrazine Nicotinamide). Nicotinyl-containing HYNIC
derivatives have been shown to be effective in tagging Tc-99m
with annexin V, single chain VEGF, EGF and others [23,24,40].
Our results clearly showed the advantage of using SPECT method
in detecting higher expression of VEGFRs in the PTK787 treated
tumors, which are in agreement with the western blot findings.
Despite the presence of VEGFR2 in the normal brain we could
not detect any activity of Tc-99m-HYNIC-VEGF in the normal
brain, which is due to intact blood brain barrier (BBB). However,
the increased uptake of Tc-99m-HYNIC-VEGF in the PTK787
treated tumors might be due to active extravasation (due to BBB
disruption and leakiness of dilated vessels as shown by tomato
lectin staining) and it’s attachment to the receptors expressed in
the tumor cells and neovessels. Despite the loss of BBB in vehicle
treated tumors (indicated by post contrast T1WI on MRI), Tc-
99m tagged VEGF did not show increased activity in the tumors,
which might indicate less neo-angiogenesis and lower amount of
VEGFRs compared to that of PTK787 treated tumors.
Clinical Implication
The results of these studies may have direct impact on the
current clinical trials as well as the future anti-angiogenic therapy
strategy, not only for glioma but for any other hypervascular
tumors. Instead of relying only on MRI modality to follow up the
patients, investigators may have a better alternative, the use of
nuclear medicine techniques (both SPECT and PET) in
determining the expression of various pro-angiogenic receptors
during anti-angiogenic therapy as well as the ability to change the
therapeutic strategy according to the findings. Further new
therapies that serve as an improvement or even as an alternative
to present treatments are needed. A newer treatment strategy
should be designed to target not only the pro-angiogenic receptors
but also the sources and the effects of angiogenic factors.
Conclusion
Dynamic contrast-enhanced MRI (DCE-MRI) using a high
molecular weight (MW) contrast agent (albumin-(GdDTPA))
showed significantly increased K
trans at the rims of the treated
tumors compared to that of the central part of the treated as well
as untreated (vehicle treated) tumors. Size of the tumors was also
increased in the treated group. The expression of VEGFR2
detected by Tc-99m-HYNIC-VEGF SPECT was also significantly
increased in the treated tumors. In PTK787 treated tumors,
histological staining revealed increase in microvessel density in the
close proximity to the tumor margin, while similar increased
vascularity was not observed in vehicle treated tumors. Western
blot analysis indicated increased expression of VEGF, SDF-1 and
HIF-1a at the peripheral part of the treated tumors, compared to
that of vehicle-treated and central part of the treated tumors.
These findings indicate that PTK treatment may induced the
over-expression of VEGF as well as the Flk-1/VEGFR2 receptor
tyrosine kinase, especially at the rim of the tumor as proven by
DCE-MRI, SPECT imaging and immunohistochemistry.
Materials and Methods
Ethics Statement
All animal experiments were performed according to NIH
guideline and the protocol was approved by institutional animal
care and user committee (IACUC) of Henry Ford Health System.
Animal Model
Athymic nude rat 6–8 weeks of age and 150–170g of weight
(Charles River Laboratory, Inc.) was anesthetized by intraperito-
neal injection using ketamin/xylazine mixture (100 mg/kg
ketamine, 15 mg/kg xylazine) and was placed on a stereotactic
head holder. The surgical zone was shaved and swabbed with
betadine solution, the eyes coated with Lacri-lube and the animal
was immobilized in a small animal stereotactic device (Kopf,
Cayunga, CA). After draping, a 1-cm incision was made 2 mm to
the right of the midline, 1 mm retro-orbitally and the skull was
exposed with cotton-tip applicators. A HP-4 dental drill bit was
used with a micromanipulator to drill a hole 3 mm to the right and
1 mm anterior to the bregma, with the care not to penetrate the
dura. A #2701 10 mL Hamilton syringe with a #4 point, 26s
gauge-needle containing tumor cells (4610
5)i n5 ml was lowered to
the depth of 3.5 mm, then raised to the depth of 2.5 mm. The
PTK787 Therapy in Rat Glioma
PLoS ONE | www.plosone.org 8 January 2010 | Volume 5 | Issue 1 | e8727U251 cells were injected stepwise at a rate of 0.5mL/30 sec until
the entire volume had been injected. During and after the
injection, careful note was made of any reflux from the injection
site. Two to three minutes after completing the injection the
syringe was withdrawn in a stepwise manner. The surgical hole
was sealed with a bone wax. Finally, the skull was swabbed with
betadine before suturing the skin over the injection site. Total 44
animals were included in this study.
Treatment with PTK787
Animals were randomly assigned to either the drug treatment
(n=24) or the control group (vehicle treated, n=20). The control
group was fed by gavage with solvent and the drug group was
treated, also by gavage, with PTK787 tyrosine kinase inhibitor (a
generous gift from Novartis, Basel, Switzerland). PTK787 was
prepared for oral administration as follows: PTK787 was
suspended in distilled water containing 5% of DMSO and 15%
of sucrose. PTK was administered orally by gavage, once a day at
a dose of 50 mg/kg per feeding. Drug administration started 7
days after tumor implantation and continued for five days in a
row. Then, after the two days interval, drug administration was
continued for another five days. On 22nd day, analyses were
performed as follows: 1) group of animals underwent in vivo MRI,
2) group of animals underwent SPECT scanning with Tc-99m-
HYNIC VEGF- and 3) group of animals were euthanized to
collect non-perfused brain including tumors for western blotting
study.
In Vivo MR Imaging and Image Analysis
MR contrast media. Albumin-(GdDTPA) is a prototype of a
water-soluble macromolecular contrast medium with 6 nm
hydrodynamic diameter, synthesized in our laboratory following
the method by Ogan et al. [41]. Albumin-(GdDTPA) was injected
during imaging at a dose of 0.03 mmol Gd/kg. Although
Albumin-(GdDTPA) is not a candidate for clinical application
due to the slow and incomplete clearance and potential induction
of immunologic toxicity, it has been used extensively in
many experimental tumor models [42,43,44]. Blood volume and
microvascular permeability were previously quantitatively
estimated using kinetic models and correlated with histological
analysis of capillary density [42,45,46].
Image acquisition. Rats were studied by MRI 22 days after
implanting the tumor cells (U251). Rats were anesthetized with
2.0% isoflurane in oxygen carrier gas and secured to a customized
cradle. A 26g dental catheter was inserted into a tail vein to
facilitate the injection of contrast agents and while rats were in the
MRI magnet the body temperature was maintained at 37.0uC.
MR images were obtained with a 3.0 Tesla clinical system (Signa
Excite, GE health) using 50 mm diameter6108 mm RF rung
length small animal imaging coil (Litzcage small animal imaging
system, Doty Scientific Inc, Columbia, SC). Pre- and post-contrast
T1-weighted (T1W), T2-weighted (T2W), and three dimensional
spoiled gradient echo (3D SPGR) images of the tumor bearing
brain were acquired before and sequentially for 20 minutes
after intravenous injection of Albumin-(GdDTPA). The three-
dimensional field of view (FOV) of the image covered the entire
brain. The following parameters were used to acquire the images.
For T1W-image; TR=625 ms, TE=15 using a 1606128 matrix,
FOV=35 mm, and NEX=4, effective slice thickness was 1 mm
and 15 slices were imaged. For multiecho T2WI; TR=2100 ms,
TE=15, 30, 45 and 60 using a 1606128 matrix, FOV=35 mm,
and NEX=2. Effective slice thickness was 1 mm and 15 slices
were imaged. To generate T1 map from precontrast images, 3D
SPGR images with multiple flip angles 2u,4 u,8 u,1 2 u, and 15u
were acquired. For dynamic post contrast 3D SPGR, a fixed flip
angle of 15u was used. The following parameters were used to
acquire the 3D SPGR images; TR=11.3 ms, TE=1.8 ms using
a 1286128 matrix, FOV=40640640 mm
3, and NEX=1.
Effective slice thickness was 1 mm.
Kinetic analysis. We used the dynamic contrast-enhanced
MR images and the following Patlak model to estimate the K
trans
and the cerebral fPV (Vp) maps [47,48].
Ct(t)~Ktrans
ð t
0
Cp(t)e
Ktrans
Ve (t{t)dtzVpCp(t) ð1Þ
where Ve is the fractional volume of the extracellular volume and
Ct(t) and Cp(t) are the tissue and the plasma concentrations over
time, respectively. Dynamic contrast-enhanced MR imaging was
performed using a transverse T1-weighted 3D SPGR acquisition
that consisted of five precontrast and 51 dynamic post contrast
images obtained up to 20 minutes after contrast injection. The
K
trans and Vp maps were generated by fitting the Patlak model in
Eq. (1) to the gathered dynamic images using TOPPCAT software
package [49,50]. The K
trans and fPV maps at the periphery and
the center of the tumors (both treated and control) were
determined by drawing rectangular regions of interests (ROIs).
The sizes of the ROIs were identical.
MR data analysis. To determine the changes in signal
intensity at each time point following the administration of
contrast agents, ROIs were drawn in the tumor periphery, tumor
center and in the contralateral normal hemisphere. The sizes of
the ROIs were identical for the three areas. The signal intensity
changes were normalized to that of corresponding contralateral
hemisphere using the following formula:
signal intensity in the tumor (rim or center)/signal intensity in the
contralateral hemisphere
A dynamic curve indicating normalized signal intensity changes
over time were created using Microsoft Office Excel 2003 software
(Microsoft, CA). Tumor size was calculated from T1-weighted
image sets obtained 24 min after Albumin-(GdDTPA) injection.
Slices that showed enhanced areas were analyzed by defining a
region of interest around the section of enhancement and
measuring the area (cm
2). The volume was calculated by
multiplying by the slice thickness. This procedure was repeated
for all slices showing enhancement and the areas were summed to
determine a total tumor volume (cm
3).
SPECT Study
Rat VEGF-c. Rat recombinant VEGF-C was purchased from
Prospec (Israel). VEGF-C, also known as Vascular Endothelial
Growth Factor Related Protein (VRP), is a recently discovered
member of VEGF growth factor family that is most closely related
to VEGF-D. Rat VEGF-C cDNA encodes a pre-pro-protein of
416 amino acids residues and it is almost identical to mouse
VEGF-C protein. Similar to VEGF-D, VEGF-C has a VEGF
homology domain spanning the middle third of the precursor
molecule and long N- and C-terminal extensions. Recombinant
rat VEGF-C, lacking the N- and C-terminal extensions and
containing only the middle VEGF homology domain, forms
primarily non-covalently linked dimers. This protein is a ligand for
both VEGFR-2/KDR and VEGFR-3/FLT -4.
Preparation of Hydrazine Nicotinamide (HYNIC).
Succinimidyl 6-hydrazinopyridine-3-carboxylate hydrochloride
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described [51]. The protein conjugate was purified with a
Centricon C-3 diafilter with a 3,000 molecular weight cutoff.
Then, the nicotinyl hydrazine conjugate of VEGF was radio
labeled with
99mTc-pertechnetate in the presence of tricine and
stannous chloride as reported by Blankenberg et al. [22]
Image acquisition. An appropriate state of anesthesia was
obtained using ketamine/xylazine 100/15 mg/kg. One hour after
IV injection of 1 mCi Tc-99m-HYNIC-VEGF-c, SPECT images
were obtained using a modified PRIZM 3000 gamma camera
dedicated to animal studies and fitted with multi pinhole
collimators (Bioscan, DC). The following image parameters were
used: 2566256 matrix, 360u rotations, 10 projections, 180 sec per
projection and 469 cm FOV. Total SPECT image acquisition
time was 31 minutes. After the SPECT analysis animals were
euthanatized and different tissues were collected for further
analysis. The projection images were reconstructed with
HiSPECT software (Bioscan, DC).
Western Blotting
Animals used for western blot analysis were euthanized and
fresh brains were collected (without perfusion), the tumor as well as
contralateral brain were separated and snapped frozen. The
collected frozen tumors were cut into peripheral and central
portions, as described in our previous publication [27]. Tissues
from the contralateral brain and the tumors were mechanically
pulverized over dry ice and total protein (30–80 mg of the frozen
tissue powder per sample) was extracted using ProteoExtractH
Complete Mammalian Proteome Extraction Kit (Calbiochem-
H,USA) according to the manufacturer’s instructions. Protein
concentration in recovered protein extracts was determined using
BioRad Protein Assay Dye Reagent Concentrate (Bio-Rad
Laboratories) using Bovine Serum Albumin (BSA) as a standard.
Forty microgram of total protein were resolved by electrophoresis
using 8–12% SDS polyacrylamide gels, transferred to the
nitrocellulose membrane (BioRad) and probed with specific
primary antibodies: anti–VEGF (Santa Cruz Biotechnology,
USA), anti-VEGFR2 (Upstate Biotech, USA), anti-VEGFR3
(Millipore, USA) anti-EGFR (Santa Cruz Biotechnology, USA),
anti-SDF-1 (Santa Cruz Biotechnology, USA) and anti-HIF-1a
(Lab Vision, USA). Primary antibody binding was detected by
incubating the membrane in the presence of horseradish
peroxidase (HRP) conjugated secondary polyclonal goat antibody
and the signal was detected by enhanced chemiluminescence using
the ECL Detection Kit (Amersham Biosciences). Density of the
western blot images were normalized to corresponding b-actin and
contralateral brain. The rectangular region of interest (ROI) was
kept identical for all measurements. The following formula was
used to normalization: ((density value of the band of interest/
corresponding density value of b-actin)/density value of the
corresponding band in contralateral brain)*100).
Histopathology
Animals used for histochemical analysis were euthanized,
perfused by intracardiac injection of 100 ml PBS followed by
3% paraformaldehyde and brains were removed and fixed in 3%
paraformaldehyde containing 3% sucrose. Tissue sections were
prepared from either frozen or paraffin tissue preparations.
Standard histochemical staining procedures were performed as
recommended by the suppliers of primary antibodies. The
following antibodies were used to delineate the expression of
corresponding antigens; anti-VEGFR2 antibody (Thermoscienti-
fic), anti-EGFR antibody (Santa Cruz Biotechnology, USA),
anti-VEGFR3 antibody (Millipore, USA), anti-VEGF antibody
(Thermoscientific), anti-SDF-1 antibody (Santa Cruz Biotechnol-
ogy, USA) and anti-HIF1a antibody (Lab Vision, USA) To
delineate the endothelial lining FITC labeled tomato lectin
(Vectashield) was used.
Statistical analysis. All data are expressed as mean 6standard
error of mean (SEM). Comparison between drug and vehicle treated
groups was done by Student’s t-test. Any p-value of ,0.05 was
considered significant.
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